1. Home
  2. DCTH vs VYGR Comparison

DCTH vs VYGR Comparison

Compare DCTH & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • VYGR
  • Stock Information
  • Founded
  • DCTH 1988
  • VYGR 2013
  • Country
  • DCTH United States
  • VYGR United States
  • Employees
  • DCTH N/A
  • VYGR N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • VYGR Biotechnology: Pharmaceutical Preparations
  • Sector
  • DCTH Health Care
  • VYGR Health Care
  • Exchange
  • DCTH Nasdaq
  • VYGR Nasdaq
  • Market Cap
  • DCTH N/A
  • VYGR 309.7M
  • IPO Year
  • DCTH N/A
  • VYGR 2015
  • Fundamental
  • Price
  • DCTH $11.87
  • VYGR $6.45
  • Analyst Decision
  • DCTH Strong Buy
  • VYGR Strong Buy
  • Analyst Count
  • DCTH 4
  • VYGR 9
  • Target Price
  • DCTH $21.50
  • VYGR $16.44
  • AVG Volume (30 Days)
  • DCTH 489.1K
  • VYGR 570.6K
  • Earning Date
  • DCTH 11-08-2024
  • VYGR 11-12-2024
  • Dividend Yield
  • DCTH N/A
  • VYGR N/A
  • EPS Growth
  • DCTH N/A
  • VYGR N/A
  • EPS
  • DCTH N/A
  • VYGR 0.47
  • Revenue
  • DCTH $22,644,000.00
  • VYGR $163,784,000.00
  • Revenue This Year
  • DCTH $1,605.13
  • VYGR N/A
  • Revenue Next Year
  • DCTH $111.67
  • VYGR N/A
  • P/E Ratio
  • DCTH N/A
  • VYGR $13.83
  • Revenue Growth
  • DCTH 945.91
  • VYGR 3.40
  • 52 Week Low
  • DCTH $2.84
  • VYGR $5.19
  • 52 Week High
  • DCTH $12.88
  • VYGR $11.72
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 61.82
  • VYGR 51.85
  • Support Level
  • DCTH $11.42
  • VYGR $6.13
  • Resistance Level
  • DCTH $12.79
  • VYGR $7.44
  • Average True Range (ATR)
  • DCTH 0.66
  • VYGR 0.34
  • MACD
  • DCTH 0.15
  • VYGR 0.09
  • Stochastic Oscillator
  • DCTH 74.17
  • VYGR 56.00

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: